A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/30/2019
Start Date:February 2016
End Date:May 2026
Contact:Acerta Clinical Trials
Email:acertamc@dlss.com
Phone:1-888-292-9613

Use our guide to learn which trials are right for you!

A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination With Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects With Mantle Cell Lymphoma

This is a multicenter, open-label Phase 1b study to assess the safety and efficacy of
acalabrutinib when administered concomitantly with bendamustine and rituximab in subjects
with treatment naive or relapse refractory mantle cell lymphoma (Part 1), or when
administered concomitantly with venetoclax and rituximab in subjects with treatment naive
mantle cell lymphoma (Part 2).


Inclusion Criteria:

- Men and women ≥ 18 years of age.

- Pathologically confirmed MCL.

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

- Agreement to use highly effective forms of contraception during the study and for 2
days after the last dose of acalabrutinib, 30 days after the last dose of venetoclax,
or 12 months after the last dose of rituximab, whichever is longest.

- Treatment Naive MCL patients requiring treatment with no exposure to prior therapies.

Exclusion Criteria:

- Significant cardiovascular disease such as uncontrolled or untreated symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart
Association Functional Classification.Exception: Subjects with controlled,
asymptomatic atrial fibrillation during screening are allowed to enroll on study

- Malabsorption syndrome, disease significantly affecting gastrointestinal function,
resection of the stomach, extensive small bowel resection that is likely to affect
absorption, symptomatic inflammatory bowel disease, partial or complete bowel
obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass

- Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as
exhibiting ongoing signs/symptoms related to the infection and without improvement,
despite appropriate antibiotics or other treatment), or intravenous anti-infective
treatment within 2 weeks before first dose of study drug

- Breastfeeding or pregnant

- Concurrent participation in another therapeutic clinical trial.
We found this trial at
10
sites
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Bologna,
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Florham Park, NJ
Click here to add this to my saved trials
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials